ARTICLE | Clinical News
LCZ696 regulatory update
February 23, 2015 8:00 AM UTC
FDA accepted and granted Priority Review to an NDA from Novartis for LCZ696 to treat heart failure with reduced ejection fraction. The PDUFA date is in August; a specific date was not disclosed. Novar...